- Lung Cancer
  - Non-small cell lung cancer (NSCLC)
    - Non-Squamous
      - ▼**10512:** A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
    - Advanced NSCLC
      - **10313**: A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/ Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
      - **10327**: A Phase I Trial of MLN0128(TAK-228) and CB-839 HCL (telaglenastat) in Advanced NSCLC Patients
    - NSCLC with presence or absence of known EGFR mutation
      - **10216:** A Phase I/II Study of AZD9291(Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer
    - NSCLC with presence or absence of known KRAS mutation
      - **10166:** A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
  - Small cell lung cancer (SCLC)
    - SCLC
      - **10268:** Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer (Exploratory cohort includes patients with extrapulmonary small cell cancers)
      - **10402:** BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
      - **10445**: Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Extensive-Stage Small Cell Lung Cancer